Anne Floquet
Research Subjects
Anne Floquet has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Isabelle Ray-Coquard
Centre Léon Bérard and Université Claude Bernard, Lyon, France
87 shared publications - Gwenaël Ferron
Department of Surgical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
86 shared publications - Alain Puisieux
Centre Léon Bérard, Lyon, France
85 shared publications - Alain Viari
Bioinformatics Platform Gilles Thomas, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1 , Synergie Lyon Cancer Fondation, 69008 Lyon
85 shared publications - Amandine Charreton
Réseau des généticiens du Grand Ouest GEM-EXCELL, Fédération Hospitalo-Universitaire Génétique Omiques Médecine et Société (GenOMedS), Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, ERN-ITHACA, CHU de Rennes, Rennes, Brittany, France
85 shared publications - Anne-Pierre Morel
Centre L eon B erard, Cancer Research Centre of Lyon, Equipe Labellis ee Ligue contre le Cancer, Lyon, France
85 shared publications
Latest Publications
- Open Access
- 4 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
- 4 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1
Open AccessAuthor Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
- Top Cited PapersOpen Access
- 5 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic activity. This open-label phase 2 study (NCT04015739) aimed to assess activity and safety of this triple combination in female patients with relapsed high-grade AOC following prior platinum-based therapy. Patients were treated with olaparib (300 mg orally, twice daily), the bevacizumab biosimilar FKB238 (15 mg/kg intravenously, once-every-3-weeks), and durvalumab (1.12 g intravenously, once-every-3-weeks) in nine French centers. The primary endpoint was the non-progression rate at 3 months for platinum-resistant relapse or 6 months for platinum-sensitive relapse per RECIST 1.1 and irRECIST. Secondary endpoints were CA-125 decline with CA-125 ELIMination rate constant K (KELIM-B) per CA-125 longitudinal kinetics over 100 days, progression free survival and overall survival, tumor response, and safety. Non-progression rates were 69.8% (90%CI 55.9%-80.0%) at 3 months for platinum-resistant relapse patients (N = 41), meeting the prespecified endpoint, and 43.8% (90%CI 29.0%-57.4%) at 6 months for platinum-sensitive relapse (N = 33), not meeting the prespecified endpoint. Median progression-free survival was 4.1 months (95%CI 3.5–5.9) and 4.9 months (95%CI 2.9–7.0) respectively. Favorable KELIM-B was associated with better survival. No toxic deaths or major safety signals were observed. Here we show that further investigation of this triple combination may be considered in AOC patients with platinum-resistant relapse.
- 5 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Top Cited PapersOpen AccessBevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic activity. This open-label phase 2 study (NCT04015739) aimed to assess activity and safety of this triple combination in female patients with relapsed high-grade AOC following prior platinum-based therapy. Patients were treated with olaparib (300 mg orally, twice daily), the bevacizumab biosimilar FKB238 (15 mg/kg intravenously, once-every-3-weeks), and durvalumab (1.12 g intravenously, once-every-3-weeks) in nine French centers. The primary endpoint was the non-progression rate at 3 months for platinum-resistant relapse or 6 months for platinum-sensitive relapse per RECIST 1.1 and irRECIST. Secondary endpoints were CA-125 decline with CA-125 ELIMination rate constant K (KELIM-B) per CA-125 longitudinal kinetics over 100 days, progression free survival and overall survival, tumor response, and safety. Non-progression rates were 69.8% (90%CI 55.9%-80.0%) at 3 months for platinum-resistant relapse patients (N = 41), meeting the prespecified endpoint, and 43.8% (90%CI 29.0%-57.4%) at 6 months for platinum-sensitive relapse (N = 33), not meeting the prespecified endpoint. Median progression-free survival was 4.1 months (95%CI 3.5–5.9) and 4.9 months (95%CI 2.9–7.0) respectively. Favorable KELIM-B was associated with better survival. No toxic deaths or major safety signals were observed. Here we show that further investigation of this triple combination may be considered in AOC patients with platinum-resistant relapse.
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
List of differentially expressed genes (paired analysis of 5 selected tumors).
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
List of differentially expressed genes (paired analysis of 5 selected tumors).
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
List of differentially methylated gene promoters (paired analysis of 5 selected tumors).
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
List of differentially methylated gene promoters (paired analysis of 5 selected tumors).
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Alteration of chromatin remodeling genes in uterine and ovarian CS.
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Alteration of chromatin remodeling genes in uterine and ovarian CS.
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Genomic landscape of CS. A, Tissue origin and histological subtypes for each tumor (from P01 to P15). B, Main component and detailed percentage content for both samples (a and b) derived from the same tumor. C, CNA analysis: tumor purity (%), ploidy, FGA, and CNA breakpoints number. D, SV number, classified as deletion, duplication, inversion, and interchromosomal translocation. E, SNV and small indel number. F, Proportion of each of four mutational signatures deciphered in the whole cohort. G, MSI phenotype: MSI score (representing the percentage of unstable microsatellite loci), MLH1 promoter methylation (beta-value), and mRNA expression level (TPM – transcripts per million). H, Kataegis number illustrating APOBEC error-prone DNA repair process. I, BRCAness phenotype: number of LST, (white stars highlight samples with LST number ≥20), BRCA1 promoter methylation level (beta-value), BRCA1/2 genes alterations and TDP score, collectively summarized by the HRD status track.
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Genomic landscape of CS. A, Tissue origin and histological subtypes for each tumor (from P01 to P15). B, Main component and detailed percentage content for both samples (a and b) derived from the same tumor. C, CNA analysis: tumor purity (%), ploidy, FGA, and CNA breakpoints number. D, SV number, classified as deletion, duplication, inversion, and interchromosomal translocation. E, SNV and small indel number. F, Proportion of each of four mutational signatures deciphered in the whole cohort. G, MSI phenotype: MSI score (representing the percentage of unstable microsatellite loci), MLH1 promoter methylation (beta-value), and mRNA expression level (TPM – transcripts per million). H, Kataegis number illustrating APOBEC error-prone DNA repair process. I, BRCAness phenotype: number of LST, (white stars highlight samples with LST number ≥20), BRCA1 promoter methylation level (beta-value), BRCA1/2 genes alterations and TDP score, collectively summarized by the HRD status track.
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Figure S16 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Complete clonal evolution of P15 tumor.
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S16 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Complete clonal evolution of P15 tumor.
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
BRCAness feature: tandem duplicator phenotype.
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
BRCAness feature: tandem duplicator phenotype.
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Figure S9 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Clustering of somatic copy number alterations profiles.
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Clustering of somatic copy number alterations profiles.
- Open Access
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Figure S8 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Alteration of genes of RAS pathway in uterine and ovarian CS.
- 10 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Alteration of genes of RAS pathway in uterine and ovarian CS.